English | 繁體

Search in the results

UM

Browse/Search Results:  1-3 of 3 Help

Selected(0)Clear Items/Page:    Sort:
TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance Journal article
Jiang,Xiao ming, Xu,Yu lian, Yuan,Luo wei, Zhang,Le le, Huang,Mu yang, Ye,Zi han, Su,Min xia, Chen,Xiu ping, Zhu,Hong, Ye,Richard D., Lu,Jin jian. TGFβ2-mediated epithelial–mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance[J]. Acta Pharmacologica Sinica, 2020, 42(3), 451-459.
Authors:  Jiang,Xiao ming;  Xu,Yu lian;  Yuan,Luo wei;  Zhang,Le le;  Huang,Mu yang; et al.
Favorite | TC[WOS]:40 TC[Scopus]:39  IF:6.9/7.6 | Submit date：2021/03/01
Egfr Mutant Non-small Cell Lung Cancer  Emt  Nf-κb  Osimertinib Resistance  Tgfβ2  
TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance Journal article
Jiang, XM, Xu, YL, Yuan, LW, Zhang, LL, Huang, MY, Ye, ZH, Su, MX, Chen, X. P., Zhu, H, Ye, R, Lu, J.. TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance[J]. Acta Pharmacologica Sinica, 2020, 451-459.
Authors:  Jiang, XM;  Xu, YL;  Yuan, LW;  Zhang, LL;  Huang, MY; et al.
Favorite |  | Submit date：2022/08/26
Egfr Mutant Non-small Cell Lung Cancer  Nf-κb  Tgfβ2  Epithelial-mesenchymal Transition  Osimertinib Resistance  
Characterization of osimertinib (AZD9291)-resistant non-small-cell lung cancer NCI-H1975/OSIR cell line Conference paper
Tang, ZH, Jiang, XM, Guo, X, Fong, CM, Wang, ZY, Chen, X. P., Lu, J.. Characterization of osimertinib (AZD9291)-resistant non-small-cell lung cancer NCI-H1975/OSIR cell line[C], 2016.
Authors:  Tang, ZH;  Jiang, XM;  Guo, X;  Fong, CM;  Wang, ZY; et al.
Favorite |  | Submit date：2022/08/26
osimertinib  resistance  EGFR  ABT-263